Personal breast: Customizing agents and biomarkers for optimal adjuvant endocrine therapy

Breast Cancer Research and Treatment

Volumn 120, Issue 2, 2010, Pages 437-439

  Bardia, Aditya ^a   Stearns, Vered ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BIOLOGICAL MARKER; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; PLACEBO; PROGESTERONE RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

AGE DISTRIBUTION; BONE DENSITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RISK; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; FAMILY HISTORY; HORMONE BLOOD LEVEL; HUMAN; IMAGE ANALYSIS; MAMMOGRAPHY; NOTE; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK BENEFIT ANALYSIS; SAMPLE SIZE; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MAMMOGRAPHY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77950690093     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0787-1     Document Type: Note

References (12)

1. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J et al (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23(3):619-629 (Pubitemid 46224240)
2. Wolfe JN (1976) Breast patterns as an index of risk for developing breast cancer. AJR Am J Roentgenol 126(6): 1130-1137
3. Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ (1998) Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev 7(12): 1133-1144 (Pubitemid 29001671)
4. Greendale GA, Palla SL, Ursin G, Laughlin GA, Crandall C, Pike MC, Reboussin BA (2005) The association of endogenous sex steroids and sex steroid binding proteins with mammographie density: results from the Postmenopausal Estrogen/Progestin Interventions Mammographic Density Study. Am J Epidemiol 162(9):826-834 (Pubitemid 41541366)
5. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G (2003) Postmenopausal hormone therapy and change in mammographie density. J Natl Cancer Inst 95(l):30-37 (Pubitemid 36124293)
6. Atkinson C, Warren R, Bingham SA, Day NE (1999) Mammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen. Cancer Epidemiol Biomarkers Prev 8(10):863-866 (Pubitemid 29508720)
7. Cuzick J, Warwick J, Pinney E, Warren. RM, Duffy SW (2004) Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst 96(8):621-628 (Pubitemid 38584986)
8. Cigler T, Tu D, Yaffe MJ, Findlay B, Verma S, Johnston D, Richardson H, Hu H, Qi S, Goss PE (2009) A randomized, placebo-controlled trial (NCIC CTG MAPI) examining the effects of letrozole on mammographie breast density and other end organs in postmenopausal women. Breast Cancer Res Treat, doi: 10.1007/s10549-009-0662-0
9. Fabian CJ, Kimler BF, Zalles CM, Khan QJ, Mayo MS, Phillips TA, Simonsen M, Metheny T, Petroff BK (2007) Reduction in proliferation with six months of letrozole in women on hormone replacement therapy. Breast Cancer Res Treat 1.06(1):75-84 (Pubitemid 47498093)
10. Vachon CM, Ingle JN, Suman VJ, Scott CG, Gottardt H, Olson JE, Goss PE (2007) Pilot study of the impact of letrozole vs. placebo on breast density in women completing 5 years of tamoxifen. Breast 16(2):204-210 (Pubitemid 46499237)
11. McTiernan A, Chlebowski RT, Martin C, Peck JD, Aragaki A, Pisano ED, Wang CY, Johnson KC, Manson JE, Wallace RB et al (2009) Conjugated equine estrogen influence on mammographie density in postmenopausal women in a substudy of the women's health initiative randomized trial. J Clin Oncol 27(36):6135-6143
12. Hartar R, Maller O, McDaniel S, Hansen KC, Hedman KJ, Lyons TR, Lucia S, Wilson RS Jr, Schedin P (2009) Tamoxifen induces pleiotrophic changes in mammary stroma resulting in extracellular matrix that suppresses transformed phenotypes. Breast Cancer Res 11(1):R5